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Abstract
Background: Parkinson’s disease (PD) is the most common 
neurodegenerative disease after Alzheimer’s dementia. 
Whereas the exact etiology of PD remains unknown, risk of 
developing PD seems to be related to a combination of ge-
netic and environmental factors. This also includes abnormal 
exposure to trace elements of nutritional and toxicological 
interest. Objectives: In this systematic review and meta-
analysis, we summarized the results of case–control studies 
comparing levels of selenium, copper, iron, and zinc in PD 
patients and controls in either blood (whole blood, serum/
plasma) or cerebrospinal fluid (CSF). Methods: We per-
formed a systematic PubMed search selecting studies re-
porting trace element levels in different specimens of pa-
tients and controls. We performed a meta-analysis using a 
random-effect model to compute the weighted mean differ-
ences (WMD) and corresponding 95% CI of selenium, cop-
per, iron, and zinc levels in the blood or CSF of patients and 
their matched controls. Results: We retrieved 56 papers re-
porting data for selenium (cases/controls: 588/721), copper 
(2,190/2,522), iron (2,956/3,469), and zinc (1,798/1,913) con-
tents in CSF and blood. Cases showed considerably higher 
levels of selenium in CSF compared with controls (+51.6%; 
WMD 5.49; 95% CI 2.82 to 8.15), while levels in serum were 
similar (–0.2%; WMD –0.22; 95% CI –8.05 to 7.62). For copper, 
cases showed slightly higher levels in CSF and slightly lower 
concentrations in serum (+4.5%; WMD 1.87; 95% CI –3.59 to 
7.33, and –4.5%; WMD –42.79; 95% CI –134.35 to 48.76, re-
spectively). A slight increase was also found for CSF iron 
 levels (+9.5%; WMD 9.92; 1.23 to 18.61), while levels were 
 decreased in serum/plasma (–5.7%; WMD –58.19; 95% 
CI –106.49 to –9.89) and whole blood (–10.8%; WMD –95.69; 
95% CI –157.73 to –33.65). Conversely, for zinc cases exhib-
ited lower levels both in CSF (–10.8%; WMD –7.34; 95% CI 
–14.82 to 0.14) and serum/plasma (–7.5%; WMD –79.93; 95% 
CI –143.80 to –16.06). A longer duration of the disease tends 
to be associated with overall lower trace element levels in 
either CSF or blood. Conclusions: Due to the study findings 
and the greater relevance of the CSF compartment com-
pared with the circulating peripheral ones, this meta-analy-
sis suggests that overexposure in the central nervous system 
to selenium, and possibly to copper and iron, may be a risk 
factor of the disease, while zinc might have a protective 




Parkinson’s disease (PD) is a neurodegenerative disor-
der with predominantly motor manifestations such as aki-
nesia and bradykinesia, tremor, muscle stiffness, and pos-
tural instability [1]. Nonmotor symptoms also exist, includ-
ing anxiety, depression, and constipation. These clinical 
manifestations are the result of dopaminergic neuron death. 
Dopaminergic neurons are cells located in the pars com-
pacta of substantia nigra, a mesencephalic section entrusted 
with dopamine synthesis and release. PD is recognized as 
the most common neurological disorder after Alzheimer’s 
dementia [2]. In industrialized countries, the prevalence is 
approximately 0.3% in the general population, with in-
creasing value in the elderly, that is, 1.0% in people aged ≥60 
years, and 3.0% in those aged ≥80 years [1, 3]. Overall, PD 
annual incidence ranges from 8 to 18 per 100,000 inhabit-
ants, with a male-to-female ratio around 1.5. Since ageing is 
the most important risk factor, its prevalence and burden 
are expected to increase over the next decades [1, 4, 5].
Although the exact cause of PD remains unknown, it 
seems to be related to interrelation of genetic and environ-
mental factors [6, 7]. For instance, caffeine [3] and in a 
more controversial way smoking [8, 9] have been suggested 
as possible protective factors, while exposure to pesticides, 
especially rotenone and paraquat, derivatives of 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine, traumatic brain in-
juries, and occupational exposure to pesticides and heavy 
metals appear to be detrimental risk factors for the disease 
[3]. Additionally, alterations in trace element homeostasis 
have been suggested to play a role in the etiology of PD-
related neurodegeneration. In particular, abnormal levels 
of some heavy metals and metalloids, such as selenium, 
copper, iron, and zinc, can adversely affect the nervous sys-
tem through the induction of reactive oxygen species pro-
duction [10–12]. However, the role of selenium and other 
trace elements is still controversial, and the recent available 
reviews on the topic are either missing or out-of-date.
We carried out an updated systematic review and me-
ta-analysis, in which we summarized the results of case-
control studies reporting levels of selenium, copper, iron, 
and zinc in the blood and cerebrospinal fluid (CSF) of PD 
patients compared with controls. 
Methods
Literature Search
We performed a systematic search in the PubMed/Medline da-
tabase using the MeSH Terms “PD” and “trace elements” (includ-
ing individual elements) through July 4, 2019 (Box 1 of Fig. 1). 
Inclusion criteria were studies carried out in humans, observation-
al design, and reporting levels of selenium, copper, iron, and zinc 
in either whole blood, serum, plasma, or CSF. Exclusion criteria 
were studies not carried out in humans, those not having an obser-
vational design or not reporting trace element contents, those in-
cluding cases of Parkinsonism, autoptic studies, studies evaluating 
levels of elements other than selenium, copper, iron, and zinc, and 
those carried out in tissues rather than whole blood, serum, plasma 
or CSF. 
Data Extraction
For each study, we extracted the year of publication, country of 
region and sample size, data about demographic characteristics of 
cases and controls (i.e., age and sex), and, for cases, disease dura-
tion and severity score (Hoehn and Yahr stage of disease [13]). For 
each study population, we extracted the trace element levels into a 
database in different specimens (whole blood, serum, plasma, and 
CSF), as mean ± SD in µg/L or median and interquartile range, 
when these were the only available data [14–17]. When only means 
or medians with their range were reported, we calculated SD = 
range/4. When the interquartile range was reported, we computed 
SD as (Q3–Q1)/1.35 and, when only 95% CI was reported, we cal-
culated SD as ([95% CI-mean]/1.96] *√n [18]. We converted levels 
reported in µmol/L into molar mass. When there were > 1 group of 
cases or controls [19–22], we computed a combined weighted 
mean and SD (online suppl. Table S1; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000502357 for detailed 
methods).
For 1 study [23], we asked the authors to kindly provide addi-
tional data not reported in the paper. Moreover, for a study in 
which 2 sets of cases and controls were reported [24], the few pa-
tients with longer-duration PD (6.0 ± 4.6 years) and the controls 
with the lowest age were not included in our analysis, to make 
cases and controls comparable for age (60.8 and 61.2 years, respec-
tively). Finally, serum selenium levels in 1 study appeared to be 
entirely implausible due to extremely low values in patients, as it 
was the case with serum iron levels in both cases and controls in 2 
studies. Thus, we excluded these studies from further analysis 
about serum levels [25–27].
Data Analysis
We performed a meta-analysis of the mean differences of trace 
element levels in cases and controls on the basis of data extracted 
from the abovementioned studies, using a random-effect model to 
account for possible study heterogeneity (assessed with the I2 sta-
tistic). We computed a weighted mean difference (WMD) with 
corresponding 95% CI of serum/plasma, whole blood, and CSF 
levels of selenium, copper, iron, and zinc. We also assessed publi-
cation bias by using funnel plots according to each biomarker of 
exposure. We carried out all statistical analyses with the Stata-15.1 
package, by using the “metan” routine (Stata Corp., TX 2019).
Results
We originally identified a total number of 555 arti-
cles through PubMed/Medline. From these, we exclud-
ed 475 studies which, after title and abstract screening, 
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were not relevant (Fig. 1). After a full-text evaluation of 
the remaining papers, we excluded 19 more papers for 
the reasons reported in Figure 1. We also excluded re-
peated or overlapping publications, by removing the 
earliest or the most incomplete ones [28–36]. We even-
tually selected 61 case-control studies for the present 
review (Table 1). These studies reported mean trace ele-
ment levels in specimens such as whole blood (n = 2), 
plasma and serum (n = 50), red blood cells (n = 2), hair 
(n = 1), and CSF (n = 14). Of these, 56 studies could be 
included in our meta-analysis, while the remaining 5 
were only used in narrative synthesis. For selenium, we 
retrieved data on 588 cases and 721 controls (based on 
3 studies on CSF and 11 on serum/plasma); for copper, 
2,190 cases and 2,522 controls (10 studies on CSF and 
28 on serum/plasma); for iron, 2,956 cases and 3,469 
controls (12 studies on CSF, 32 on serum/plasma, and 2 
on whole blood); for zinc, 1,798 cases and 1,913 controls 
(7 studies on CSF and 21 on serum/plasma). Overall, 
these studies were published between 1967and 2019 and 
carried out in different countries: 43% in Europe (n = 
24, of which 9 in Italy and 5 in Spain), 37% in Asia (n = 
21, of which 7 in India and 7 in China), and 20% in 
America (n = 11, 7 in the United States and 5 in South 
America).
Most studies reported age and sex of study subjects, 
while disease duration was available only in 29 of the 61 
studies considered in the descriptive analysis reported in 
Table 1 and disease severity in 19 studies. Two studies as-
sessed serum iron levels [15] and copper levels [37] only 
in men, while the remaining ones evaluated trace ele-




























Full-text articles excluded, with
reasons (n = 19)
• Duplicate studies or results on the
 same population (n = 9)
• Element levels not reported (n = 5)
• PD not considered in outcomes (n = 4)












Search strategy up through July 4, 2019:
(PD[MH] OR Parkinson[tiab] OR Parkinson)
AND
(trace elements OR metals OR microelements OR selenium[MH]) OR selenium[tiab] OR
iron[MH] OR iron[tiab] OR copper[MH] OR copper[tiab] OR zinc[MH] OR zinc[tiab])
AND
(serum OR CSF OR plasma OR blood)
Fig. 1. Flow chart summarizing study iden-
tification and selection and reporting de-
tails of PubMed search strategy, up through 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































We could analyze data from 12 studies (Table 2). For 
serum/plasma selenium concentrations, there was al-
most no difference between the weighted average levels 
in cases and controls (WMD –0.22 µg/L, 95% CI –8.05 
to 7.62), while selenium concentrations in the CSF were 
considerably higher in patients (+ 51.6%), based on 3 
studies (WMD +5.49 µg/L, 95% CI 2.82–8.15). There 
was little evidence of publication bias (online suppl. Fig. 
S1). Heterogeneity for serum/plasma selenium levels 
was very high (98.1%), while for studies based on 
CSF levels it amounted to 60.3% (Fig. 2). Average sele-
nium levels across the studies were substantially simi-
lar, apart from 2 old Spanish studies [38, 39] and a 

























































































Fig. 2. Mean difference in individual studies and summary WMD of selenium levels (µg/L) in serum/plasma 
and in CSF in patients with PD compared with controls. WMD, weighted mean difference; CSF, cerebrospinal 
fluid. 
Table 2. WMD of the trace element concentrations (in µg/L) between patients with PD and controls, with corresponding 95% CI and 
percentage difference in patients (%)
Element Matrix Studies, n WMD 95% CI Difference, %
Selenium CSF 3 5.49 2.82 to 8.15 +51.6
Serum/plasma 11 –0.22 –8.05 to 7.62 –0.2
Whole blood / / / /
Copper CSF 10 1.87 –3.59 to 7.33 +4.5
Serum/plasma 28 –42.79 –134.35 to 48.76 –4.5
Whole blood / / / /
Iron CSF 12 9.92 1.23 to 18.61 +9.5
Serum/plasma 32 –58.19 –106.49 to –9.89 –5.7
Whole blood 2 –95.69 –157.73 to –33.65 –10.8
Zinc CSF 7 –7.34 –14.82 to 0.14 –10.8
Serum/plasma 21 –79.93 –143.80 to –16.06 –7.5
Whole blood / / / /
WMD, weighted mean difference; PD, Parkinson’s disease; CSF, cerebrospinal fluid.
Selenium, Trace Elements and PD 13Neuroepidemiology 2020;54:1–23
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Copper
As shown in Table 2, average CSF copper concentra-
tions were slightly higher (+4.5%) in patients than in con-
trols (WMD +1.87, 95% CI –3.59 to 7.33), whereas se-
rum/plasma copper levels were slightly lower in patients 
(–4.5%, WMD –42.79, 95% CI –134.35 to 48.76 – Fig. 3). 
Some slight evidence of publication bias emerged, as 
shown in online Supplementary Figure S1. Heterogeneity 
was very high in both analyses (I2 = 99.7 and 96.5% for 
serum/plasma and CSF levels, respectively, Fig. 3). Aver-
age copper concentrations measured in CSF varied con-
siderably across studies, while copper mean levels in se-
rum/plasma were considerably more similar. Results did 
not substantially change when we restricted the analysis 
to earlier PD cases only, as reported in 2 studies [40, 41] 
with serum/plasma WMD –39.54 (95% CI –131.22 to 
52.14 and CSF WMD 2.01, 95% CI –3.34 to 7.35; online 
suppl. Fig. S2). 
Iron
Based on 33 studies, iron levels in plasma or serum were 
slightly lower in patients (–5.7%; WMD –58.19 µg/L, 95% 
CI –106.49 to –9.89), and this was also true for whole 
blood concentrations as reported in 2 studies (–10.8%; 














































































































































































































Fig. 3. Mean difference in individual studies and summary WMD of copper levels (µg/L) in serum/plasma and 
in CSF in patients with PD compared with controls. WMD, weighted mean difference; CSF, cerebrospinal fluid. 
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WMD –95.69, 95% CI –157.73 to –33.65 – Table 2 and 
Fig. 4). Conversely, CSF iron content was slightly higher 
(+9.5%) in patients compared with controls (WMD 9.92 
µg/L, 95% CI 1.23–18.61). By repeating the analysis re-
stricted to patients with shorter duration PD in 1 study 
[41], results changed little (serum/plasma WMD –55.31, 
95% CI –103.38 to –7.24; online suppl. Fig. S3). High het-
erogeneity characterized both studies based on serum or 
plasma levels (I2 = 95.6%) and those reporting CSF levels 
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Fig. 4. Mean difference in individual studies and summary WMD of iron levels (µg/L) in serum/plasma, whole 
blood, and in CSF in patients with PD compared with controls. WMD, weighted mean difference; CSF, cerebro-
spinal fluid. 
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trations (Fig. 4). Some asymmetry in funnel plot suggest-
ed some publication bias in favor of lower trace element 
levels in patients for studies based on CSF, while there was 
little indication of such bias for studies on serum/plasma 
iron levels (online suppl. Fig. S1). Average iron concen-
trations did not differ between PD patients and controls 
across most studies, with the exception of 4 studies for 
CSF levels [21, 27, 42, 43] and 2 for serum/plasma mean 
concentrations [44, 45]. 
Zinc
In the 24 studies investigating this trace element, aver-
age zinc levels were lower in PD cases than in controls, 
both in CSF (–10.8%; WMD –7.34, 95% CI:–14.82 to 
0.14) and serum/plasma (–7.5%; WMD –79.93, 95% 
CI –143.80 to –16.06), as shown in Table 2. No study in-
vestigated zinc levels in whole blood. The heterogeneity 
of results was 95.1% in studies examining CSF levels and 
98.1% for those based on plasma/serum concentrations 
(Fig. 5). By repeating the analysis restricted to patients 
with shorter duration PD in 1 study [41], results did not 
change substantially (online suppl. Fig. S4). Some evi-
dence of publication bias in favor of lower levels in PD 
patients emerged for both serum/plasma and CSF matri-
ces (online suppl. Fig. S1).
Sensitivity Analyses
Some studies allowed to compare trace element levels 
in patients with recent PD diagnosis compared with those 
with longer disease duration (Table 3 and Fig. 6). Gellein 
et al. [46] detected higher serum trace element levels in 19 
PD subjects sampled few months to few years before PD 
diagnosis, compared with values detected in the same pa-
tients several years (4–12 years) after disease diagnosis, 




























































































































































Fig. 5. Mean difference in individual studies and summary WMD of zinc levels (µg/L) in serum/plasma and in 
CSF in patients with PD compared with controls. WMD, weighted mean difference; CSF, cerebrospinal fluid.  
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particularly for selenium and to a lesser extent for iron, 
copper, and zinc. Two of the 5 studies that analyzed cop-
per serum levels in patients with different PD clinical du-
ration found higher levels in patients with longer disease 
duration [19, 20], while 2 other studies found lower con-
centrations in this subgroup [24, 40, 41]. Takahashi et al. 
[24] compared trace element concentrations in PD pa-
tients with recent PD diagnosis (disease duration 2.0 ± 1.3 
years) with those detected in patients with longer disease 
duration (6.0 ± 4.6 years), finding lower levels of seleni-
um, copper, and zinc in patients with longer PD clinical 
course, while iron serum concentrations were higher. 
Hegde et al. [41] found lower levels of iron and zinc in 
patients with long-term illness, both in serum/plasma 
and CSF.
Discussion
In this systematic review and meta-analysis, we sum-
marized the results of case–control studies comparing lev-
els of selenium, copper, iron and zinc in patients with PD 
and controls in different biological matrices. To the best 
of our knowledge, this is the first meta-analysis assessing 
biomarkers of selenium levels and PD. We found similar 
selenium exposure in the serum or plasma of PD patients 
compared with controls, while CSF levels were consider-
ably higher in PD patients. Such increased CSF selenium 
contents may either suggest that selenium overexposure 
in the central nervous system plays a role in disease etiol-
ogy or indicate the occurrence of selective derangements 
of the trace element status as a consequence of disease on-
set and progression. The possible causal association be-
tween increased selenium exposure and PD risk is also 
supported by recent epidemiological findings showing an 
excess PD mortality in individuals exposed to selenium in 
its inorganic hexavalent form through drinking water 
[47]. Although conflicting evidence has been reported by 
nonhuman studies on the involvement of selenium in PD 
etiology [48], there is biological plausibility for such asso-
ciation. Selenium is a nutritionally essential element in the 
human owing to several properties such as its antioxidant 
activity, regulation of Ca2+ channels, and modulation of 
neurogenesis [49]. Nevertheless, selenium may also exert 
many adverse effects on several body systems including 
the central nervous system, encompassing the induction 
of oxidative stress and other mechanisms [50–54]. In par-
ticular, selenium might adversely affect dopaminergic 
neurons, since selenium overexposure may lead to neuro-
degeneration through the generation of reactive oxygen 
species and the alteration of mRNA expression of dopa-
mine receptors, tyrosine hydroxylase, and dopamine 
transporter genes [55–59]. Selenium neurotoxicity may 
occur even at very low levels [60, 61], and it has been 
Table 3. Studies comparing trace element levels in patients with PD with shorter and longer disease duration
Study Matrix Element Shorter duration
mean ± SD, µg/L
Longer duration
mean ± SD, µg/L
Arnal et al. [19], 2010 Plasma Copper 870±20 1,020±40
Bharucha et al. [20], 2008 Serum Copper 995±278 1,044±272
Boll et al. [40], 1999 CSF Copper 5.04±3.89 4.21±3.12




Hegde et al. [41], 2004 Serum Copper 1,398±508.4 1,271±381.3
Iron 1,117±223.3 949.4±390.9
Zinc 523.0±130.8 457.7±65.4
Takahashi et al. [24], 1994 Serum Selenium 150±70 120±20
CSF Copper 30±33 24±5
Serum Copper 1,390±350 1,090±600
CSF Iron 140±150 100±40
Serum Iron 1,690±610 2,030±1,050
CSF Zinc 280±200 210±140
Serum Zinc 1,880±760 1,700±690
PD, Parkinson’s disease; CSF, cerebrospinal fluid.
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Copper levels in serum/plasma
Fig. 6. Comparison of trace element levels (µg/L) in serum/plasma and CSF according to PD duration. Dark gray 
box: shorter PD duration, light gray box: longer PD duration, whiskers: SD. CSF, cerebrospinal fluid. 
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shown that this element activates the p38 pathway [62], a 
mechanism implicated in PD etiopathogenesis [63].
Concerning copper and iron, we updated previous re-
views by adding 9 and 18 studies, respectively [64, 65]. Dif-
ferently from previous reviews that could not identify ap-
preciable differences between element levels in PD cases 
and controls, we found higher CSF levels in PD cases, while 
levels were lower in serum, plasma, and whole blood. A 
potential relevance of both copper and iron elements in PD 
etiopathogenesis has been reported by many investigators, 
including neurotoxic effects that may occur through dif-
ferent mechanisms [66–68]. Dusek et al. [69] suggested 
that iron metabolism dysregulation in substantia nigra is 
related to neurodegeneration. More recently, a synergistic 
mechanism between copper and iron has been suggested, 
with evidence for an interaction of these elements with 
α-synuclein [11, 70–73]. Copper and iron, such as other 
redox active metals, may also affect protein aggregation 
through the generation of free oxygen radicals [74, 75]. In 
addition, impaired distribution of iron may lead to brain 
damage, and excess iron in the brain is a hallmark of neu-
rodegenerative disorders such as Alzheimer’s disease and 
amyotrophic lateral sclerosis [76–79]. 
In PD patients, selenium, copper, and iron all showed 
higher levels in CSF, but lower ones in serum/plasma or 
whole blood compared with controls. Such different find-
ings for the same elements were not entirely unexpected. 
In fact, it has been shown that CSF trace element levels 
and their corresponding peripheral, circulating levels 
may not correlate, particularly in subjects with PD and 
other neurodegenerative diseases often related to im-
paired nutritional status [80–82]. In particular, alteration 
of metal transporters and/or alterations in blood-brain 
barrier may occur in these patients, affecting the CSF/
blood ratio of trace elements [83–85]. Lack of correlation 
between CSF and blood trace element levels may also 
stem from peculiarities in CNS detoxification system 
[86]. For selenium, some of its species, namely the inor-
ganic ones, did not correlate between blood and CSF in 
healthy subjects, differently from the organic chemical 
forms [87, 88]. 
In terms of biological relevance and etiologic signifi-
cance, we consider CSF trace element levels of higher im-
portance than the blood ones. CSF is a biological matrix 
secreted by the central nervous system and forms an in-
tegral part of it, thus becoming highly relevant to the di-
agnosis of neurodegenerative diseases [89–91] including 
PD [92]. CSF is directly connected, without a barrier, to 
the extracellular space of brain parenchyma and facili-
tates molecular exchange. The composition of CSF and 
extracellular brain fluids is similar, and a misbalance or 
exposure and depletion of elements in the brain are re-
flected by CSF [93]. The importance of element levels in 
CSF as a biomarker of central nervous system exposure, 
compared with indicators in peripheral matrices such as 
serum/plasma or whole blood, is widely appreciated, also 
reflecting metabolic processes underlying brain paren-
chyma functioning [87, 94]. Therefore, under an etiolog-
ic perspective, the increased trace element contents in the 
CSF of PD patients compared with controls are more im-
portant than the opposite findings for serum/plasma lev-
els of these trace elements. In fact, the exposure within the 
central nervous system may be considered most relevant 
to PD (or more generally to neurodegenerative diseases) 
etiology, compared with peripheral exposure. This is par-
ticularly true for selenium, which showed by far the high-
est percent increase in CSF levels compared with the oth-
er trace elements tested. Conversely, no change in blood 
levels was detected, emphasizing how poorly this bio-
marker may mirror central nervous system exposure.
When assessing average trace element levels according 
to PD clinical duration, we generally observed lower lev-
els in patients with longer-term illness, suggesting that 
PD progression is associated with a reduction of circulat-
ing trace element levels. This means that the higher CSF 
levels of these elements, and particularly of selenium, that 
we found in our meta-analysis are more likely to be in-
volved in the causal pathway of the disease than to be an 
effect of disease itself. Alternatively, higher CSF levels 
may simply predict or accompany disease onset. Con-
versely, the low trace element levels detected in overall PD 
patients or in those selectively having a long clinical 
course are likely to be a consequence of disease itself, due 
to either an impaired nutritional status [80–82] or an al-
teration of trace element metabolism due to disease pro-
gression. Some studies assessed trace elements intake 
through diet in relation with PD risk, yielding inconsis-
tent results though with some indication of a positive as-
sociation with iron intake [95, 96]. It is also possible that 
the increased CSF selenium contents may be a conse-
quence of the increased synthesis of selenoproteins, en-
zymes with antioxidant properties, in the central nervous 
system, as a compensatory response to increased reactive 
oxygen species production [97]. This might also lead to a 
concomitant reduction in blood selenium contents. How-
ever, a better understanding of the mechanisms under-
pinning selenium changes in the central nervous system 
before and during PD is hampered by lack of data on 
changes of CSF selenium content according to disease du-
ration. Overall, the findings for the other elements in both 
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CSF and blood, and for selenium in blood, appear to con-
firm an etiologic role of high exposure to selenium, 
though less strongly to iron and copper, in PD etiology.
Based on 24 studies (a double number of the previous 
meta-analysis), we found lower zinc concentrations in 
both CSF and blood of PD patients, consistently with a 
possible role of zinc deficiency in disease etiopathogene-
sis. Our findings mirror those of a recent meta-analysis 
that evaluated the association between zinc serum levels 
and PD [98]. These results are of interest in light of role of 
zinc as an antioxidant enzyme cofactor, the increased ox-
idative stress following decreased zinc levels [99–102], 
and finally the observation that zinc supplements may im-
prove PD severity in animal models [103]. Recent studies 
have underlined the key role of dysregulation of zinc con-
centration and its synergic interaction with dopaminergic 
system in both cells and animal models [104, 105]. How-
ever, the observation that zinc levels inversely correlated 
with PD duration in the few studies assessing such asso-
ciation raises the possibility of reverse causation, that is, 
of an effect of disease itself in decreasing zinc status. This 
suggests caution in hypothesizing that zinc deficiency may 
be a risk factor, and not a consequence, of PD.
We must acknowledge some limitations in the re-
viewed studies and in the results of this meta-analysis. 
First, particularly for some elements and matrices, the 
number of studies and their size were too low to yield a 
satisfactory statistical precision of the summary effect es-
timates, as shown by their wide confidence intervals. In 
addition, in several studies some relevant details of study 
population were lacking, such as PD duration and clinical 
severity in patients. Moreover, all studies we retrieved 
were case-control, a study design that may induce spuri-
ous associations from an etiological point of view. In fact, 
reverse causation is a key issue in assessing the etiological 
role of trace elements, as recently shown for selenium in 
Alzheimer’s dementia by comparing the case-control 
with the longitudinal study design [106]. A further limita-
tion also was that some reviewed studies included a con-
trol population who might not have been completely ap-
propriate. In fact, they had undergone sample analysis 
because of some neurological symptoms, in turn possible 
related to trace element alterations and to potential selec-
tion bias. As previously mentioned, finally, no speciation 
analysis was available in the studies reviewed. This is a 
major limitation in light of what we know from the few 
available speciation studies on central nervous system 
disease, showing the relevance of the chemical forms of 
elements such as selenium or iron, and how speciation 
analysis may lead to entirely different results in the same 
study [89, 91, 107]. Nowadays, elemental speciation fos-
ters important links between powerful techniques, from 
analytical chemistry to neurodevelopment or brain de-
generation research [50]. Element speciation analysis has 
matured to provide key knowledge by investigating 
changes in both species concentration and the pattern of 
essential elements (e.g., SELENOP vs. Se [IV]) [89], or 
shifts in their redox pairs (e.g., Fe [II] vs. Fe [III] [108]). 
As such, it would definitively allow for deeper insights 
into the molecular mechanisms and pathways of PD. It 
would therefore be of fundamental importance to con-
firm and expand the scope of our study, by performing 
elemental speciation analysis for selenium as well as the 
other trace elements [89, 108]. 
In conclusion, our meta-analysis indicates that, despite 
their lower peripheral circulating trace element levels, PD 
patients exhibit higher levels of copper, iron, and particu-
larly selenium in CSF compared with referents. Such high-
er exposure might be a risk factor of PD, rather than a 
consequence of the disease, consistent with the biological 
plausibility of these associations. This seems to be particu-
larly true for selenium, given some recent epidemiological 
and toxicological evidence on how its species may ad-
versely affect dopamine metabolism. The decreased zinc 
levels found in PD patients also deserve careful scrutiny, 
since it might indicate a role of zinc deficiency in disease 
etiology, though we could not entirely rule out the possi-
bility of reverse causation about this finding.
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